Abstract:Objective To investigate the clinical effect of short-term glucocorticoid(GC)combined with nucleoside analogues in the treatment of patients with severe hepatitis.Methods The clinical data of 60 patients with severe hepatitis who were admitted to the Second Affiliated Hospital of Yichun University from January 2013 to December 2020 were retrospectively analyzed.According to different drug treatment methods,they were divided into experimental group(29 cases)and control group(31 cases).The control group was treated with antiviral nucleoside analogues and conventional medical treatment,and the experimental group was treated with GC for 5-7 days.The clinical efficacy,liver function,coagulation function and the occurrence of adverse reactions were compared between the two groups.Results There was no significant difference in clinical treatment effect between the two groups(P>0.05).The levels of total bilirubin(TBil)and alanine aminotransferase(ALT)in experimental group were lower than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in albumin(ALB)between the two groups after treatment(P>0.05).After treatment,prothrombin time(PT)and activated partial thrombin time(APTT)in experimental group were shorter than those in control group,while fibrinogen(FIB)and prothrombin activity(PTA)in experimental group were lower than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with nucleoside analogues alone,curative effect of short-term GC combined with nucleoside analogues is more significant on patients with early severe hepatitis,which can effectively improve liver function and coagulation dysfunction,with good safety.
彭芳;涂龙;廖群. 短程糖皮质激素联合核苷类似物治疗重型肝炎前期及早期患者的临床效果[J]. 中国当代医药, 2022, 29(10): 46-49.
PENG Fang ;TU Long ;LIAO Qun. Clinical effect of short-term glucocorticoids combined with nucleoside analogues in the treatment of patients with severe hepatitis. 中国当代医药, 2022, 29(10): 46-49.
Yuan L,Zeng BM,Liu LL,et al.Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection[J].World J Gastroenterol,2019,25(19):2327-2337.
[3]
Singer GA,Zielsdorf S,Fleetwood VA,et al.Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost effective prophylaxis against hepatitis B virus after liver transplantation[J].Transplant Proc,2015,47(2):478-484.